Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Levothroid 300 μg · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Levothyroxine Sodium Tablets 300 μg |
| 2 | ACTIVE_COMPARATOR | Levothroid® Tablets 300 μg |
| Name | Type | Description |
|---|---|---|
| Levothyroxine Sodium Tablets 300 μg | DRUG | 2x300mcg, single dose fasting |
| Levothroid® Tablets 300 μg | DRUG | 2x300mcg, single dose fasting |
Inclusion Criteria: 1. Age: 18-50 years. 2. Sex: Men and/or non-pregnant, non-lactating women. 1. Women of childbearing potential must have negative serum β human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to of the study and on the evening prior to each dose ad...
Levothroid 300 μg is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development, with one completed trial evaluating its effects in healthy adults. The drug is being developed by Viatris Inc.
Levothroid 300 μg is developed by Viatris Inc., a company traded on the stock exchange under the ticker VTRS. The drug is currently in Phase 1 clinical development for use in healthy volunteers.
Levothroid 300 μg is in Phase 1 clinical development. One Phase 1 trial has been completed, involving 32 healthy participants in the United States. The drug is investigational and has not been approved by regulatory authorities.
Levothroid 300 μg has one completed clinical trial, registered as NCT00648700. This was a Phase 1 fasting study comparing Levothyroxine Sodium Tablets 300 μg to Levothroid Tablets 300 μg in 32 healthy adults in the United States.
Levothroid 300 μg is a levothyroxine sodium tablet formulation. The completed clinical trial NCT00648700 was a fasting study designed to compare Levothyroxine Sodium Tablets 300 μg with Levothroid Tablets 300 μg, indicating they are being evaluated for equivalence.